US Biopharmaceuticals: EHA 2026 Abstract Planner: AGIO sNDA/confirmatory, BEAM, CRBU

Research evidence excerpt

US Biopharmaceuticals: EHA 2026 Abstract Planner: AGIO sNDA/confirmatory, BEAM, CRBU

Abstract Planner

Exhibit 1: EHA 2026 abstract planner

We highlight key presentations for companies across our coverage including BEAM, AGIO, and CRBU

Time

Company Program Type of Data (CEST) Type Abstract No. Titles Importance

June 11th

(Thursday)

BEAM SCD meta-analysis N/A Publication PB4134 Correlation Between Fetal Hemoglobin and Clinical LOW

Outcomes in Sickle Cell Disease: A Model-Based

Meta-Analysis

AGIO mitapivat Clinical N/A Publication PB4160 ENERGIZEKIDS: Mitapivat in Pediatric Patients With MODERATE

Non-Transfusion-Dependent Alpha- or

Beta-Thalassemia

AGIO mitapivat Clinical N/A Publication PB4162 ENERGIZEKIDS-T: Mitapivat in Pediatric Patients MODERATE

With Transfusion-Dependent Alpha- or

AGIO SCD / thalassemia / PKD PRO N/A Publication PB4417 The Patient Experience of Fatigue in Individuals LOW

With Sickle Cell Disease, Thalassemia, and Pyruvate

Kinase Deficiency

AGIO mitapivat Clinical 4:45 - 6:00 Oral S304 Effects of Mitapivat on Iron Burden and Spleen Size MODERATE

PM in Erythrocyte Membranopathies and Congenital

Dyserythropoietic Anemia Type II: 56-Week

Follow-Up Results From the SATISFY Study

June 12th

(Friday)

CRBU vispa-cel Clinical 5:15 - 6:30 Oral S236 Vispa-cel, an allogeneic anti-CD19 CAR-T cell therapy HIGH

PM with a PD-1 knockout, in patients with

relapsed/refractory B cell non-Hodgkin lymphoma

(ANTLER phase 1 clinical trial)

AGIO SCD TBD 6:45 - 7:45 Poster PF1264 Metabolic Profiles Associated With Point of Sickling LOW

PM Reflect Immunoregulation, Oxidative Stress, and

Compensatory Mechanisms in Patients With Sickle

Cell Anemia

AGIO SCD TBD 6:45 - 7:45 Poster PF1269 Impaired Function of Pyruvate Kinase Is Associated MODERATE